Skip to main content
MedPathMedPath Home
Clinical Trials/NCT05323227
NCT05323227
Unknown
Not Applicable

Association of Lipoprotein (a) With Coronary CTA Assessed High Risk Coronary Disease Attributes and Cardiovascular Outcomes

Shanghai Zhongshan Hospital1 site in 1 country378 target enrollmentMarch 20, 2016
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsCoronary Artery Disease

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
Shanghai Zhongshan Hospital
Enrollment
378
Locations
1
Primary Endpoint
Association of Lp(a) level with CCTA measured Parameters
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

Lipoprotein(a) [Lp(a)] is a risk factor for cardiovascular events, although the underlying mechanism remains unclear. This study evaluated the relationship between Lp(a) and high-risk attributes (HRA) by coronary computed tomography angiography (CCTA) as well as their prognostic value.

Registry
clinicaltrials.gov
Start Date
March 20, 2016
End Date
May 30, 2022
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Shanghai Zhongshan Hospital
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Patients with Lp(a) meaured within 1 week of CCTA examination.

Exclusion Criteria

  • •unstable angina pectoris
  • •acute myocardial infarction
  • •New York Heart Association class III-IV heart failure
  • •with a history of bypass surgery
  • •active infection
  • •respiratory failure
  • •chronic kidney disease (estimated glomerular filtration rate \[eGFR\] \<60 ml/min/1.73 m2)
  • •liver dysfunction (liver enzyme \>3 upper reference limit \[URL\] or bilirubin \>2 URL)
  • •malignancy
  • •systemic connective tissue disease

Outcomes

Primary Outcomes

Association of Lp(a) level with CCTA measured Parameters

Time Frame: at the index procedure

Association of Lp(a) level with CCTA measured high-risk plaque characteristics

Major adverse cardiac events

Time Frame: at 24 months from index procedure

a composite of cardiac death, any myocardial infarction, and stroke

Secondary Outcomes

  • Cardiac death(at 24 months from index procedure)
  • Myocardial infarction(at 24 months from index procedure)
  • Stroke(at 24 months from index procedure)

Study Sites (1)

Loading locations...

Similar Trials

Unknown
Not Applicable
Thrombogenicity of Lipoprotein A: Laboratory Study Defining the Prothrombotic Effects of Lipoprotein ACardiovascular Disease and Lipid DisordersCardiac Disease
NCT05330819South Tees Hospitals NHS Foundation Trust20
Recruiting
Not Applicable
Role of LipoprotEin(a) in CardiovascuLar Diseases and Premature Acute Coronary Syndromes - (RELACS) StudyAcute Coronary SyndromeLipoprotein DisorderAcute Myocardial InfarctionCardiovascular Diseases
NCT05496790University of Campania "Luigi Vanvitelli"1,000
Withdrawn
Not Applicable
Randomized Controlled Trial of Lipid Apheresis in Patients With Elevated Lipoprotein(a)Hyperlipoproteinemia(a)Progressive Cardiovascular Disease
NCT01064934Charite University, Berlin, Germany
Terminated
Not Applicable
Search a Correlation Between Lp(a) Rate and TFPI Activity in Obese Patients With Chest Pain Like AnginaAtherosclerosis
NCT01290770Centre Hospitalier Universitaire de Saint Etienne40
Completed
Not Applicable
Role of lipoproteins in cardiovascular disease - the LipidCardio studyI00-I99Diseases of the circulatory system
DRKS00020915Charité - Universitätsmedizin BerlinMedizinische Klinik für Kardiologie1,005